Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001178913-25-003465
Filing Date
2025-10-06
Accepted
2025-10-06 06:08:56
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5839
  Complete submission text file 0001178913-25-003465.txt   7821
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Subject) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-55457 | Film No.: 251375548
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address HAREL HOUSE, 3 ABBA HILLEL ST. RAMAT GAN Israel 52118
Business Address HAREL HOUSE, 3 ABBA HILLEL ST. RAMAT GAN Israel 52118 972-3-7547090
Harel Insurance Investments & Financial Services Ltd. (Filed by) CIK: 0001429390 (see all company filings)

EIN.: 981676531 | Fiscal Year End: 1231
LEI: 213800BDNN3W11SXXD60
Type: SCHEDULE 13G